Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background Irritable bowel syndrome (IBS) occurs in up to 33% of Gulf War (GW) Veterans. Alterations in gut microflora including small intestinal bacterial overgrowth (SIBO) during deployment may play a role in development of IBS. Rifaximin is a minimally absorbed antibiotic speculated to improve IBS symptoms, in part, by restoring normal gut microflora. The aim of this study was to compare rifaximin to placebo on IBS symptoms and quality of life (QOL) in GW Veterans with IBS without constipation. Methods A double-blind, placebo-controlled study was performed. One hundred and twenty-two GW Veterans with IBS (Rome III) from our database and referral to gastroenterology and internal medicine clinics were screened. After a 2-week run-in period, 50 patients were randomized (1:1) to receive either rifaximin 550 gm or placebo twice daily for 2 weeks in a double-blind study. Patients were advised not to change their diet or medications during the study. The symptoms assessed were: (1) stool frequency, (2) stool consistency (Bristol stool scale, 1-7, very hard to watery), (3) urgency (1 = yes/0 = no daily for 7 days), (4) severity of abdominal pain (0-4, none to severe), (5) severity of bloating (1-4, none to severe), and (6) global improvement scale (1-7, substantially worse to substantially improved). These were recorded for 7 consecutive days and then averaged across the 7 days, to generate a continuous variable. The symptom data were compared after 2 weeks of treatment. QOL was a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“despite this being the rationale for use of nonabsorbable antibiotics in IBS, 70 a positive breath test result does not predict response to treatment.145”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [145]
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Irritable Bowel Syndrome: A Clinical Review
Chey, W. D., Kurlander, J., & Eswaran, S. (2015) · JAMA · doi:10.1001/jama.2015.0954 · Cited by 1,081
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.46 · Cited by 852 · cited 1×
“The role of LHBT in predicting response to rifaximin treatment and as diagnostic tool for SIBO continues to be debated [25].”
BackgroundEradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Pimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669 · cited 1×
“A positive LHBT in patients with IBS has been reported in up to 84% of patients [26].”
BackgroundDerogatis, L. R. (2011) · PsycTESTS Dataset · doi:10.1037/t07502-000 · Cited by 656
Steele, L. (2000) · American Journal of Epidemiology · doi:10.1093/aje/152.10.992 · Cited by 525
Research works printed but not linked: 1
- Gulf War and Health. Update of health effects of serving in the Gulf War. Institute of Medicine: National Academy of Sciences, National Academies Press; 2016.
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
“145 Similarly, variants in the sucrase-isomaltase gene have been reported to be associated with an increased risk of IBS, 146 and some investigators have reported evidence of sucrase-isomaltase deficiency on small intestinal biopsy in patients with suspected IBS, 147 but at present there is…”
Kashyap, P., Moayyedi, P., Quigley, E. M. M., Simrén, M., & Vanner, S. J. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14817 · Cited by 73
“28,29 These studies were performed in various study populations–symptomatic individuals with SIBO, subjects with FIGURE 2 Combined Lactulose– 99m Tc scintigraphy shows the test meal is in the cecum before H 2 rises in IBS patients.”
BackgroundWang, J., Zhang, L., & Hou, X. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.2005579 · Cited by 56
Postinfection Irritable Bowel Syndrome
Ghoshal, U. C. (2021) · Gut and Liver · doi:10.5009/gnl210208 · Cited by 56
Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review
Lupu, V. V., Ghiciuc, C. M., Ștefănescu, G., Mihai, C. M., Popp, A., Săsăran, M. O., Bozomitu, L. I., Stârcea, I. M., Răileanu, A. A., & Lupu, A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i21.3241 · Cited by 56
A Systematic Review of Therapeutic Interventions and Management Strategies for Gulf War Illness
Nugent, S. M., Freeman, M., Ayers, C. K., Winchell, K. A., Press, A. M., O'Neil, M. E., Paynter, R. A., & Kansagara, D. L. (2020) · Military Medicine · doi:10.1093/milmed/usaa260 · Cited by 35
Identifying, Understanding, and Managing Fecal Urgency in Inflammatory Bowel Diseases
Caron, B., Ghosh, S., Danese, S., & Peyrin‐Biroulet, L. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.029 · Cited by 33
Mousavi, T., Nikfar, S., & Abdollahi, M. R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1767067 · Cited by 32
“Contrary to all this, Persian Gulf war veterans with nonconstipating IBS who were treated by 550 mg RFX BID, in the same duration, expressed no relief of stated symptoms and no improvement in the lactose hydrogen breath test (LHBT), the indicator of abnormal colon microbiota [78].”
BackgroundZhuang, X., Tian, Z., Luo, M., & Xiong, L. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01336-6 · Cited by 32
Irritable bowel syndrome – controversies in diagnosis and management
Duncanson, K., Tikhe, D., Williams, G. M., & Talley, N. J. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2223975 · Cited by 25
Self-citationAbou-Donia, M. B., Lapadula, E. S., Krengel, M., Quinn, E. K., LeClair, J., Massaro, J. M., Conboy, L. A., Kokkotou, E. G., Abreu, M. M., Klimas, N. G., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10090610 · Cited by 20
RetractedRecent advances in diagnosis and management of irritable bowel syndrome
den Houte, K. V., Colomier, E., Schol, J., Carbone, F., & Tack, J. F. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000628 · Cited by 21
“[40] randomized patients to either placebo or rifaximin twice daily for 2 weeks but rifaximin did not improve symptoms and no difference based on lactulose breath tests was found.”
Belgian consensus on irritable bowel syndrome
Kindt, S., Louis, H., Schepper, H. U. D., Arts, J., Caenepeel, P., Looze, D. A. D., Gerkens, A., Holvoet, T., Latour, P., Mahler, T., et al. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.10100 · Cited by 26
Guo, H., Lu, S., Zhang, J., Chen, C., Du, Y., Wang, K., & Duan, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1121435 · Cited by 23
“Studies have shown significant symptom remission of rifaximin therapy in IBS patients with SIBO (Moraru et al., 2014; Liu et al., 2016; Leite et al., 2018; Rezaie et al., 2019; Tuteja et al., 2019).”
BackgroundLiu, Z., Zhu, S., He, M., Li, M., Wei, H., Zhang, L., Sun, Q., Jia, Q., Hu, N., Fang, Y., et al. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002294 · Cited by 16
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review
Camilleri, M., & Dilmaghani, S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108400 · Cited by 13
Ramos, G. P., & Camilleri, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07700-8 · Cited by 15
“was not associated with significant improvement in global symptoms, abdominal pain, bloating, stool urgency, frequency, or consistency, or quality of life, and that normalization of SIBO by lactulose-hydrogen breath test was not different between rifaximin- and placebo-treated veterans [62].”
BackgroundAngoa‐Pérez, M., Zagorac, B., Francescutti, D. M., Theis, K. R., & Kuhn, D. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119675 · Cited by 21
“A doubleblind, placebo-controlled trial in GW Veterans with irritable bowel syndrome (IBS), a common condition in GWI, reported that the use of Abx was not associated with significant improvement in IBS-related symptoms [38].”
BackgroundShin, A., Xu, H., & Imperiale, T. F. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.08.005 · Cited by 12
Targeted pharmacotherapy of irritable bowel syndrome
Arokiadoss, A., & Weber, H. C. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000618 · Cited by 10
Iribarren, C., Maasfeh, L., Öhman, L., & Simrén, M. (2022) · Gut Microbiome · doi:10.1017/gmb.2022.6 · Cited by 9
“In parallel, numerous randomised clinical trials have reported promising results in treating IBS symptoms with rifaximin (Supplementary References: Rifaximin), although with some exceptions (Tuteja et al., 2019).”
BackgroundZhang, Q., Li, H., Chen, C., Li, M., Song, J., Pan, S., Shen, B., & Huang, Y. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251399033 · Cited by 8
Crisis in the gut: navigating gastrointestinal challenges in Gulf War Illness with bioengineering
Collier, C. A., Salikhova, A., Sabir, S., Foncerrada, S., & Raghavan, S. A. (2024) · Military Medical Research · doi:10.1186/s40779-024-00547-2 · Cited by 9
“However, this intervention did not demonstrate any in relieving symptoms such as abdominal pain, bloating, stool urgency/frequency/consistency [120].”
BackgroundEmerging evidence that irritable bowel syndrome & functional dyspepsia are microbial diseases
Talley, N. J., & Walker, M. M. (2019) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_84_19 · Cited by 6
Self-citationMicrobial Influences on Irritable Bowel Syndrome
Quigley, E. M. M. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2024.12.003 · Cited by 5
Harris, L. A. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05505-w · Cited by 5
Djotsa, A. B. S. N., Wenker, T. N., Ahmed, S. T., Ghosh, S., Malhotra, D., Boyle, S. H., Gifford, E. J., Sims, K. J., White, D. L., Steele, L., et al. (2024) · Military Medicine · doi:10.1093/milmed/usae260 · Cited by 4
Shah, Q., & Soldera, J. (2026) · World Journal of Methodology · doi:10.5662/wjm.v16.i1.107169 · Cited by 5
Arora, U., Sachdeva, K., Garg, P., Baitha, U., Kedia, S., Kalaivani, M., Ahuja, V., Kumar, A., Ranjan, P., Vikram, N. K., et al. (2023) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001872 · Cited by 4
“For the binary outcome of improvement in bloating, the analyzed studies usually had a low risk of bias in all domains except selective reporting, which was at high risk of bias 16,17 in 2 studies and unclear risk 10,15 in 2 studies.”
BackgroundMethodCommon questions and rationale answers about the intestinal bacterial overgrowth syndrome (SIBO)
González, J. A., Estremera, F., Cobián, J., Santos, J., Alcala-Gonzalez, L. G., Naves, J., Barba, E., Barber, C., Falcón, B. S., Accarino, A. M., et al. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2024.502216 · Cited by 4
Efficacy and safety of lactulose for the treatment of irritable bowel syndrome
Chen, H., & Su, X.-Y. (2019) · Medicine · doi:10.1097/md.0000000000017295 · Cited by 3
Autonomic dysfunction and gastroparesis in Gulf War veterans
Verne, Z. T., Fields, J. Z., Zhang, B. B., & Zhou, Q. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002291 · Cited by 3
Verne, Z. T., Fields, J. Z., Verne, G. N., Zhang, B. B., Thacker, A. L., & Zhou, Q. (2024) · International Journal of Gastroenterology · doi:10.11648/ijg.20240801.12 · Cited by 2
Self-citationMaslennikov, R. V., Agarkova, V., Poluektova, E., Ulyanin, A. I., Zolnikova, O., Курбатова, А. А., Kozlov, E. M., Demina, T., Zharikov, Y. O., Sigidaev, A. S., et al. (2026) · Medical Sciences · doi:10.3390/medsci14020300 · Cited by 1
Koller, A. M., Săsăran, M. O., Lupu, A., & Mărginean, C. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1908516 · Cited by 1
“In a placebo-controlled study of patients with IBS, rifaximin did not improve symptoms or breath-test outcomes compared with placebo (Tuteja et al., 2019).”
InfluentialGonzález, J. A., Estremera, F., Cobián, J., Santos, J., Alcala-Gonzalez, L. G., Naves, J., Barba, E., Barber, C., Falcón, B. S., Accarino, A. M., et al. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2024.502216 · Cited by 5
调查显示:很多大学生存在人际交往障碍,专家提示——学会沟通 尊重他人
刘京京 (2008) · 中外健康文摘
Recent advances in the treatment of functional dyspepsia and irritable bowel syndrome
BIENIASZ, J., BIGOS, P., DENDYS, K., Kuźnicki, W., Matkowski, I., & Potyrała, P. J. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.43.01.005
罗, 绪. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381893
Hospodarskyy, I., Hryshchuk, L. A., & Boyko, T. V. (2024) · GASTROENTEROLOGY · doi:10.22141/2308-2097.58.2.2024.605
Sampayo, F. H., Barreto, I. D. J. Y., & del Risco, F. G. (2025) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.1381
Iftequar, Y., Bajpai, P., Dav, R., Harshitha, K. S., Chandan, C., Goel, R., Chimkar, S. B., & Chowdhary, R. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04418-7 · Cited by 1
Metadata
- Authors
- Tuteja, A. K., Talley, N. J., Stoddard, G. J., & Verne, G. N.
- Affiliations
- University of Utah (US)
- University of Newcastle Australia (AU)
- Tulane University (US)
- Corresponding author
- Tuteja, Ashok K.
- Venue
- Digestive Diseases and Sciences
- Published
- 2018-10-28
- Volume
- 64
- Issue
- 3
- Pages
- 838-845
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2898093380
- Cited by
- 42
- References
- 33
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 8 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 3
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Department of Veterans Affairs (1I01CX001477-01)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK099052)
- Department of Defense (W81XWH-10-1-0593, W81XWH-15-1-0636)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- irritable bowel syndrome, rifaximin, lactulose breath test, small intestinal bacterial overgrowth, Gulf War veterans, quality of life, IBS symptoms, gut microbiota, antibiotic therapy, bloating, abdominal pain, stool consistency, IBS-QOL, Rome III criteria, IBS subtypes
- MeSH terms
- Gastrointestinal Microbiome, Rifaximin, Adult, Aged, Anti-Bacterial Agents, Bacteria, Breath Tests, Defecation, Double-Blind Method, Female, Humans, Lactulose, Male, Middle Aged, Predictive Value of Tests, Quality of Life, Time Factors, Veterans, Treatment Outcome, Irritable Bowel Syndrome, Gulf War
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.